AHA again urges HHS to protect 340B program from drug companies’ actions

Sep 08, 2020 - 02:39 PM
AHA-OIG-letter

The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals. 

While the Health Resources and Services Administration, which oversees the 340B program, is investigating these activities, AHA urged HHS to take “swift and decisive action to halt these pernicious tactics” to prevent other manufacturers from following suit.

“The drug companies are attempting to exploit for their financial benefit the current COVID-19 health care crisis,” AHA said. “As you are aware, hospitals throughout the nation are under severe stress by the need to prepare for, and/or care for, COVID-19 patients, while coping with the financial damages inflicted by the virus. Therefore, we urge you to act immediately against any drug manufacturer employing these pernicious tactics to ensure that 340B drugs are available and accessible to vulnerable communities.” Read the full letter here.

The AHA has engaged in numerous efforts urging the drug companies to cease these activities and have HHS take action to protect 340B hospitals. See the previous letters the AHA has sent on the issue:

Related News Articles

Headline
Rhode Island district court denies drug company efforts to block state’s 340B contract pharmacy law 
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
AHA says HRSA vastly underestimates costs 340B Rebate Pilot Program will inflict on hospitals, urges agency to delay implementation
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
AHA comments on CY 2026 OPPS proposed rule
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…